| Wuxi Pharmatech (Cayman) Inc. - SWOT Analysis | | | | operating loss of $20.9 million in FY2008. The net |
| company profile is the essential source for top-level | | | | profit of the company was $52.9 million in FY2009, as |
| company data and information. Wuxi Pharmatech | | | | compared to the net loss of $64.2 million in FY2008. |
| (Cayman) Inc. - SWOT Analysis examines the | | | | Scope of the Report |
| company's key business structure and operations, | | | | - Provides all the crucial information on Wuxi |
| history and products, and provides summary analysis | | | | Pharmatech (Cayman) Inc. required for business and |
| of its key revenue lines and strategy. | | | | competitor intelligence needs |
| Wuxi Pharmatech (Cayman) (WuXi) is a leading global | | | | - Contains a study of the major internal and external |
| pharmaceutical, biopharmaceutical and medical device | | | | factors affecting Wuxi Pharmatech (Cayman) Inc. in |
| outsourcing company. It offers a range of laboratory | | | | the form of a SWOT analysis as well as a |
| and manufacturing services across the | | | | breakdown and examination of leading product |
| discovery-to-commercialization spectrum. The | | | | revenue streams of Wuxi Pharmatech (Cayman) Inc. |
| company primarily operates in China and the US. It is | | | | -Data is supplemented with details on Wuxi |
| headquartered in Shanghai, China and employed 4,202 | | | | Pharmatech (Cayman) Inc. history, key executives, |
| people as of December 2009. The company recorded | | | | business description, locations and subsidiaries as well |
| revenues of $270 million during the financial year (FY) | | | | as a list of products and services and the latest |
| ended December 2009, an increase of 6.5% over | | | | available statement from Wuxi Pharmatech (Cayman) |
| FY2008. The operating profit of the company was | | | | Inc. |
| $52.1 million during FY2009, as compared to the | | | | |